Genome Sequence of Coxiella burnetii 109, a Doxycycline-Resistant Clinical Isolate

Rouli, Laetitia; Rolain, Jean‐Marc; Filali, Adil El; Robert, Caroline; Raoult, Didier

doi:10.1128/jb.01856-12

Cited by 34 publications

(22 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The only patient who died from endocarditis had a ratio of Ͻ0.5 (26). The whole genome of the C. burnetii strain infecting that patient (Cb109) was determined, but no specific sequence could be correlated with doxycycline resistance (27). Since then, two other isolates have been found to be resistant to doxycycline, including one goat isolate and another human isolate from a patient with acute Q fever (28).…”

Section: Search Strategymentioning

confidence: 99%

From Q Fever to Coxiella burnetii Infection: a Paradigm Change

et al. 2017

Self Cite

View full text Add to dashboard Cite

Coxiella burnetii is the agent of Q fever, or "query fever," a zoonosis first described in Australia in 1937. Since this first description, knowledge about this pathogen and its associated infections has increased dramatically. We review here all the progress made over the last 20 years on this topic. C. burnetii is classically a strict intracellular, Gram-negative bacterium. However, a major step in the characterization of this pathogen was achieved by the establishment of its axenic culture. C. burnetii infects a wide range of animals, from arthropods to humans. The genetic determinants of virulence are now better known, thanks to the achievement of determining the genome sequences of several strains of this species and comparative genomic analyses. Q fever can be found worldwide, but the epidemiological features of this disease vary according to the geographic area considered, including situations where it is endemic or hyperendemic, and the occurrence of large epidemic outbreaks. In recent years, a major breakthrough in the understanding of the natural history of human infection with C. burnetii was the breaking of the old dichotomy between "acute" and "chronic" Q fever. The clinical presentation of C. burnetii infection depends on both the virulence of the infecting C. burnetii strain and specific risks factors in the infected patient. Moreover, no persistent infection can exist without a focus of infection. This paradigm change should allow better diagnosis and management of primary infection and long-term complications in patients with C. burnetii infection.

show abstract

Section: Search Strategymentioning

confidence: 99%

From Q Fever to Coxiella burnetii Infection: a Paradigm Change

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…This included one from an endocarditis patient that died during treatment with doxycycline, one isolate from a goat, and a third from a human acute Q fever case. The genome sequence from the resistant isolate obtained from the endocarditis patient is available [47], but no potential mechanisms of resistance have been described. The extent of doxycycline resistance is not known.…”

Section: Need For Alternative Therapiesmentioning

confidence: 99%

“…Hydroxychloroquine can also cause ocular toxicity and may not be tolerated due to an impaired visual field. Although not common, isolates resistant to doxycycline have been reported [46,47]. It is therefore worthwhile to search for alternative treatments for Q fever endocarditis.…”

Section: Expert Commentary and Five-year Viewmentioning

confidence: 99%

Antimicrobial therapies for Q fever

Kersh¹

2013

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Summary Q fever is caused by the bacterium Coxiella burnetii and has both acute and chronic forms. The acute disease is a febrile illness often with headache and myalgia that can be self-limiting whereas the chronic disease typically presents as endocarditis and can be life threatening. The normal therapy for the acute disease is a two week course of doxycycline, whereas chronic disease requires 18-24 months of doxycycline in combination with hydroxychloroquine. Alternative treatments are used for pregnant women, young children, and those who cannot tolerate doxycycline. Doxycycline resistance is rare but has been reported. Co-trimoxazole is a currently recommended alternative treatment, but quinolones, rifampin, and newer macrolides may also provide some benefit.

show abstract

“…Chronic infections are treated with a combination of doxycycline and chloroquine for at least 18 months and up to 4 years (7). A recent fatal case of Q fever was caused by a doxycycline-resistant strain, and cases presenting with endocarditis are associated with frequent relapses, despite antibiotic treatment (8,9).…”

mentioning

confidence: 99%

Efficacy of Liposome-Encapsulated Ciprofloxacin in a Murine Model of Q Fever

Norville

Hatch

Bewley

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Encapsulation of antibiotics may improve treatment of intracellular infections by prolonging antibiotic release and improving antibiotic uptake into cells. In this study, liposome-encapsulated ciprofloxacin for inhalation (CFI) was evaluated as a postexposure therapeutic for the treatment of Coxiella burnetii, the causative agent of Q fever. Intranasal treatment of male A/Jola (A/J) mice with CFI (50 mg/kg of body weight) once daily for 7 days protected mice against weight loss and clinical signs following an aerosol challenge with C. burnetii. In comparison, mice treated twice daily with oral ciprofloxacin or doxycycline (50 mg/kg) or phosphate-buffered saline (PBS) lost 15 to 20% body weight and exhibited ruffled fur, arched backs, and dehydration. Mice were culled at day 14 postchallenge. The weights and bacterial burdens of organs were determined. Mice treated with CFI exhibited reduced splenomegaly and reduced bacterial numbers in the lungs and spleen compared to mice treated with oral ciprofloxacin or doxycycline. When a single dose of CFI was administered, it provided better protection against body weight loss than 7 days of treatment with oral doxycycline, the current antibiotic of choice to treat Q fever. These data suggest that CFI has potential as a superior antibiotic to treat Q fever.

show abstract

Genome Sequence of Coxiella burnetii 109, a Doxycycline-Resistant Clinical Isolate

Cited by 34 publications

References 11 publications

From Q Fever to Coxiella burnetii Infection: a Paradigm Change

From Q Fever to Coxiella burnetii Infection: a Paradigm Change

Antimicrobial therapies for Q fever

Efficacy of Liposome-Encapsulated Ciprofloxacin in a Murine Model of Q Fever

Contact Info

Product

Resources

About